RAND's divisions conduct research on a uniquely broad front for clients around the globe.
More
Research
Apr 29, 2026
This report presents educational information and insights for those who are evaluating Indiana's cannabis policies or considering potential alternatives.
Commentary
Apr 27, 2026
Pivotal parliamentary elections are coming in June, and Armenia's young democracy faces a stirring test between the ghosts of its history and a hopeful bet on a stable future.
Beau Kilmer oversees RAND's research on psychedelic use and policy which informs conversations on the topic and helps decisionmakers think through all the different policy options and to understand the potential trade-offs.
Expert Insights
The authors describe an artificial general intelligence (AGI) Rideout strategy to avoid geopolitical risks in the race toward and transition to AGI. The strategy prioritizes deterring conflicts and increasing U.S. tech infrastructure resilience.
Article
Apr 23, 2026
China's fertility decline could strain its government, undermine its security, and sap its economic energy. That may seem like an advantage for the United States, but U.S. fertility rates are slipping, too.
This report examines the CCP's "total war" national security concept, which integrates civilian and military capabilities to counter the United States.
Project
RAND Europe evaluated the first three years of the 'From Harm to Hope' drug strategy treatment and recovery portfolio in England.
Podcast
Duration 25:35
RAND's Jennie Wenger and Stephanie Bonds discuss America's disconnected youth—and what it will take to help them thrive.
Apr 22, 2026
This report summarises the methods used in evaluating the implementation of the UK government's 10-year drug strategy investment in the Treatment and Recovery Portfolio in England (D-SITAR).
This study examined how the housing support grant had been implemented in England for people who use alcohol and/or other drugs. Findings show that the grant was generally implemented as planned and appeared to fill gaps in service provision.
This process evaluation looks at the first three years of implementation of the Treatment and Recovery Portfolio of the UK government's 10-year drug strategy, From Harm to Hope.
